Methods
The co-medications included in this review concern diseases with a high prevalence or occurrence, and those commonly associated with HIV/AIDS and considered critical for patient care in sub-Saharan Africa. The WHO 2021 Model List of Essential Medicines was consulted to identify drugs of interest to our review .
Once the list of co-medications was identified, a literature search was conducted on PubMed using a predefined Boolean search strategy. The search strategy described below (Table 1) was used to identify relevant studies published up until April 2023. The search was limited to studies conducted in humans or PBPK simulation, published in English. All potentially related designs, including trials, observational studies, experimental and in silico studies, were considered in the literature search. Studies were not restricted to a particular geographical area.
In addition to the literature search, the Liverpool HIV drug interaction database was consulted to identify additional studies on DDIs between cabotegravir or rilpivirine and the predefined co-medications. This database provides a comprehensive resource for healthcare professionals, researchers, and patients to identify potential drug interactions between antiretrovirals and other medications used in clinical practice. By consulting this database, we aimed to supplement the literature search and ensure that all relevant information on potential DDIs was captured.